HS 235
Alternative Names: HS-235Latest Information Update: 11 Dec 2024
Price :
$50 *
At a glance
- Originator 35Pharma
- Class Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Activin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Obesity
- Research Musculoskeletal disorders